血液学炎症标志物在鼻咽癌中的临床应用价值

国际肿瘤学杂志››2019,Vol. 46››Issue (8): 492-495.doi:10.3760/cma.j.issn.1673-422X.2019.08.010

血液学炎症标志物在鼻咽癌中的临床应用价值

周媛媛李旌

广西壮族自治区柳州市人民医院肿瘤放疗科 545006

收稿日期:2019-04-28修回日期:2019-05-09出版日期:2019-08-08发布日期:2019-10-31
通讯作者:周媛媛 E-mail:zyy00mail@sina.com
基金资助:

广西壮族自治区卫生和计划生育委员会自筹经费科研课题（Z20170707）

Clinical practice value of hematological inflammation biomarkers in nasopharyngeal carcinoma

Zhou Yuanyuan, Li Jing

Department of Radiation Therapy, Liuzhou General Hospital, Guangxi Zhuang Autonomous Region, Liuzhou 545006, China

Received:2019-04-28Revised:2019-05-09Online:2019-08-08Published:2019-10-31
Contact:Zhou Yuanyuan E-mail:zyy00mail@sina.com
Supported by:

Self-financing Scientific Research of Health and Family Planning Commission of Guangxi Zhuang Autonomous Region (Z20170707)

摘要/Abstract

摘要：炎症可促进肿瘤的发生、发展、浸润、转移。鼻咽癌中血液学炎症标志物异常（外周血中性粒细胞淋巴细胞比值、血小板淋巴细胞比值、全身免疫炎症指数、C反应蛋白等）是炎症在肿瘤发展中的临床表现，通过对鼻咽癌患者中的血液学炎症标志物检测可获得提示预后的信息，对现有的预后指标起到补充作用，有助于指导个体化临床治疗策略的制定，为临床实践提供更多的思路。

关键词:鼻咽肿瘤,预后,血液学炎症标志物

Abstract:Inflammation promotes tumor initiate, progress, invade and metastasize. Hematological inflammation biomarkers in nasopharyngeal carcinoma (peripheral blood neurtrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index and C-creative protein) are the expressions of inflammation in the progress of nasopharyngeal carcinoma. The information of prognosis can be obtained by testing the hematological inflammation biomarkers in nasopharyngeal carcinoma patients. These biomarkers are the supplement for the current prognosis predictive indices and they can be used to guide the clinical practice, which will provide more ideas.

Key words:Nasopharyngeal neoplasms,Prognosis,Hematological inflammation biomarker

周媛媛, 李旌. 血液学炎症标志物在鼻咽癌中的临床应用价值[J]. 国际肿瘤学杂志, 2019, 46(8): 492-495.

Zhou Yuanyuan, Li Jing. Clinical practice value of hematological inflammation biomarkers in nasopharyngeal carcinoma[J]. Journal of International Oncology, 2019, 46(8): 492-495.

参考文献

［1］ Fernandes JV, Cobucci RN, Jatobá CA, et al. The role of the mediators of inflammation in cancer development［J］. Pathol Oncol Res, 2015, 21(3): 527-534. DOI: 10.1007/s12253-015-9913-z. ［2］ Oliva N, Carcole M, Beckerman M, et al. Regulation of dendrimer/dextran material performance by altered tissue microenvironment in inflammation and neoplasia［J］. Sci Transl Med, 2015, 7(272): 272ra11. DOI: 10.1126/scitranslmed.aaa1616. ［3］ Lippitz BE. Cytokine patterns in patients with cancer: a systematic review［J］. Lancet Oncol, 2013, 14(6): e218-e228. DOI: 10.1016/S1470-2045(12)70582-X. ［4］ Yao JJ, Zhu FT, Dong J, et al. Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area［J］. BMC Cancer, 2019, 19(1): 37. DOI: 10.1186/s12885-018-5236-2. ［5］李晓惠, 徐冰清, 高劲, 等. 中性粒细胞与淋巴细胞比值对鼻咽癌放射敏感性及预后影响的研究［J］. 中华放射肿瘤学杂志, 2016, 25(5): 432-435. DOI: 10.3760/ema.j.issn.1004-4221.2016.05.002. ［6］ Chua ML, Tan SH, Kusumawidjaja G, et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: a pooled analysis of two randomised controlled trials［J］. Eur J Cancer, 2016, 67: 119-129. DOI: 10.1016/j.ejca.2016.08.006. ［7］ Sun W, Zhang L, Luo M, et al. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil-lymphocyte ratio and plateletlymphocyte ratio［J］. Head Neck, 2016, 38 Suppl 1: e1332e1340. DOI: 10.1002/hed.24224. ［8］聂冬, 王若峥, 吾甫尔, 等. 治疗前PLR与NLR在评估新疆维吾尔族鼻咽癌预后价值中的初步探讨［J］. 中国医师杂志, 2016, 18(5): 647-652. DOI: 10.3760/cma.j.issn.1008-1372.2016.05.003. ［9］ Su L, Zhang M, Zhang W, et al. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma［J］. Medicine (Baltimore), 2017, 96(11): e6364. DOI: 10.1097/md.0000000000006364. ［10］ Jiang W, Chen Y, Huang J, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis［J］. Oncotarget, 2017, 8(39): 66075-66086. DOI: 10.18632/oncotarget.19796. ［11］ Jiang Y, Qu S, Pan X, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma［J］. Oncology, 2018, 9(11): 9992-10004. DOI: 10.18632/oncotarget.24173. ［12］ Ye L, Oei RW, Kong F, et al. Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy［J］. Eur Arch Otorhinolaryngol, 2018, 275(5): 1309-1317. DOI: 10.1007/s00405-018-4956-x. ［13］ Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma［J］. Clin Cancer Res, 2014, 20(23): 6212-6122. DOI: 10.1158/1078-0432.CCR-14-0442. ［14］ Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer［J］. World J Gastroenterol, 2017, 23(34): 6261-6272. DOI: 10.3748/wjg.v23.i34.6261. ［15］ Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study［J］. Ann Surg, 2019, 270(1): 139-146. DOI: 10.1097/SLA.0000000000002660. ［16］ Fest J, Ruiter R, Mulder M, et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer-a population-based cohort study［J］. Int J Cancer, 2019, Inpress. DOI: 10.1002/ijc.32303. ［17］ Oei RW, Ye L, Kong F, et al. Prognostic value of inflammation-based prognostic index in patients with nasopharyngeal carcinoma: a propensity score matching study［J］. Cancer Manag Res, 2018, 10: 2785-2797. DOI: 10.2147/CMAR.S171239. ［18］ Fang Y, Xu C, Wu P, et al. Prognostic role of C-reactive protein in patients with nasopharyngeal carcinoma［J］. Medicine (Baltimore), 2017, 96(45): e8463. DOI: 10.1097/MD.0000000000008463. ［19］ Zeng YC, Wu R, Xiao YP, et al. Serum C-reactive protein predicts poor prognosis in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy［J］. Curr Oncol, 2015, 22(1): 20-24. DOI: 10.3747/co.22.2178. ［20］ Tang LQ, Hu DP, Chen QY, et al. Elevated highsensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy Era［J］. PLoS One, 2015, 10(4): e0122965. DOI: 10.1371/journal.pone.0122965. ［21］ Chen R, Zhou Y, Yuan Y, et al. Effect of CRP and kinetics of CRP in prognosis of nasopharyngeal carcinoma［J］. Front Oncol, 2019, 9: 89. DOI: 10.3389/fonc.2019.00089. ［22］ Chen QY, Tang QN, Tang LQ, et al. Pretreatment serum amyloid A and C-reactive protein comparing with Epstein-Barr virus DNA as prognostic indicators in patients with nasopharyngeal carcinoma: a prospective study［J］. Cancer Res Treat, 2018, 50(3): 701-711. DOI: 10.4143/crt.2017.180. ［23］ Liu X, Sun X, Liu J, et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer［J］. Transl Oncol, 2015, 8(4): 339-345. DOI: 10.1016/j.tranon.2015.06.006. ［24］ Ishizuka M, Nagata H, Takagi K, et al. Clinical significance of the C-reactive protein to albumin ratio for survival after surgery for colorectal cancer［J］. Ann Surg Oncol, 2016, 23(3): 900-907. DOI: 10.1245/s10434-015-4948-7. ［25］ Gao N, Yang RN, Meng Z, et al. The prognostic value of C-reactive protein/albumin ratio in nasopharyngeal carcinoma: a meta-analysis［J］. Biosci Rep, 2018, 38(6): pii: BSR20180686. DOI: 10.1042/BSR20180686. ［26］ Zhang Y, Zhou GQ, Liu X, et al. Exploration and validation of C-reactive protein/albumin ratio as a novel inflammation-based prognostic marker in nasopharyngeal carcinoma［J］. J Cancer, 2016, 7(11): 1406-1412. DOI: 10.7150/jca.15401. ［27］ Tao CJ, Chen YY, Jiang F, et al. The C-reactive protein/albumin ratio is an independent prognostic factor for overall survival in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy［J］. J Cancer, 2016, 7(14): 2005-2011. DOI: 10.7150/jca.16210. ［28］ Wang Y, Yang L, Xia L, et al. High C-reactive protein/albumin ratio predicts unfavorable distant metastasis-free survival in nasopharyngeal carcinoma: a propensity score-matched analysis［J］. Cancer Manag Res, 2018, 10: 371-381. DOI: 10.2147/cmar.s155604. ［29］ Sun P, Chen C, Xia Y, et al. The ratio of C-reactive protein/albumin is a novel inflammatory predictor of overall survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma［J］. Dis Markers, 2017, 2017: 6570808. DOI: 10.1155/2017/6570808. ［30］ He S, Wang Y, Chen H, et al. C-reactive protein/albumin ratio (CAR) as a prognostic factor in patients with non-metastatic nasopharyngeal carcinoma［J］. J Cancer, 2016, 7(15): 2360-2366. DOI: 10.7150/jca.16443. ［31］ Li XH, Chang H, Xu BQ, et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study［J］. Cancer Med, 2016, 6(1): 310-319. DOI: 10.1002/cam4.947. ［32］ Chen C, Sun P, Dai QS, et al. The Glasgow prognostic score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma［J］. PLoS One, 2014, 9(11): e112581. DOI: 10.1371/journal.pone.0112581. ［33］ Li JP, Chen SL, Liu XM, et al. A novel inflammation-based stage (Ⅰ stage) predicts overall survival of patients with nasopharyngeal carcinoma［J］. Int J Mol Sci, 2016, 17(11): pii. E1900. DOI: 10.3390/ijms17111900.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[6]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞.原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[7]	万芳, 杨钢, 李睿, 万启晶.食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[8]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[9]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[10]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[11]	彭琴, 蔡玉婷, 王伟.KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[12]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[13]	金旭东, 陈忠坚, 毛伟敏.MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[14]	黄镇, 陈永顺.循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[15]	王潇, 李盈, 罗玉杰, 晋舒.基于列线图模型探讨血清学指标对鼻咽癌预后的判断价值[J]. 国际肿瘤学杂志, 2023, 50(8): 463-469.